Mark I. Greene, M.D., Ph.D., F.R.C.P.
Dr. Greene is the John W. Eckman Professor of Medical Science and Director of Immunobiology and Experimental Pathology Division at University of Pennsylvania. From 1980 to 1986, he was an Associate Professor of both Harvard University and Harvard Medical School. In 1986, Dr. Greene joined the University of Pennsylvania and became the head of Immunology Research and Professor of Pathology and Laboratory Medicine.
His groundbreaking work in the functions of human erbB receptor led to the development of Herceptin (Genentech). His research also leads to the development of a proprietary method for the rapid, reliable design of allosteric inhibitors of receptors and enzymes. He has received multiple patents in the area of antibody and mimetic based cancer therapy, as well as in the engineering of antibody complementary determining regions. He has concentrated on antibody atomic structure and function for the last 30 years.
Dr. Greene\'s laboratory developed an approach to target and down-modulate oncoproteins which when expressed were critical for abnormal malignant cell growth. This simple approach developed in the neu system involved developing monoclonal antibodies specific for the ectodomain of pl85. This was the basis for targeted therapy and the approach has led to improved treatment for early and advanced breast cancer.
Dr. Greene has been recognized with many awards for his work, including Allyn Taylor Prize, Adams County Breast Cancer Research Award and the Cotlove Award. In 2011 Dr. Greene was made an honorary fellow of Lincoln College, Oxford University.
Yin Chen, Ph.D.
Dr Yin Chen is a successful serial entrepreneur with extensive experience in pharmaceutical product research & development, company operation/project management as well as international business development that includes drafting and negotiating in/out licensing and partnership deals. He also has many years’ experience in biotech venture investment that includes sourcing, due diligence and negotiation. Dr. Chen is the founder and President of BioMedfield Consulting which founded in 2014. Over 18 years, he had built and sold multiple companies in the biotech industry. he was co-founder and CEO of MTT Pharmaceuticals, where he led all aspects of the company’s operation. Prior to that, he was CSO of a startup biotech company, where managed both business development and R&D for the company.
Guangli Wang, Ph.D.
Dr. Wang has strong expertise in protein engineering and production, bioprocess development, and therapeutic antibody production, with over twenty years’ experience in biotech and biopharma industry. He is currently a Co-founder and General Manager of Euprotein, Inc. Previously he served OriGene as Vice President who steered the company’s production and business of protein department across three facilities globally. At OriGene, he successfully launched the largest human antigen collection that was instrumental to antibody and assay development for both research and diagnostic applications. Prior to joining OriGene, he held the Director and Manager positions in several biotech companies including Laureate Pharma, a protein therapeutics development and manufacturing service company. During his tenure at Laureate Pharma, Dr. Wang involved extensively in early development and technology transfer of therapeutic antibody production processes and GMP manufacturing. Dr. Wang received his Ph.D. in Biochemistry from Rutgers and finished his postdoctoral training in Princeton University. Over the years, Dr. Wang has gained deep understanding with the market of life science products, as well as strong leadership and managerial skills in biotech industry.